Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 7,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · derivative · entry 4 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC |
ABERNETHY MATTChief Financial Officer
|
GrantStock Option · Derivative | 44,632 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · derivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 2,030 | $116.81 | $237,115.98 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,869 F3 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:30 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 880 | $116.85 | $102,825.54 |
DisclosureSEC source: 0001209191-21-009132 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,043 F1 · kind: Sale of 880 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,549) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.9394 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantRestricted Stock Unit · Derivative | 532 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · derivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 532 Underlying: Common Stock · 532 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC |
Bozigian Haig P.Chief Development Officer
|
GrantStock Option · Derivative | 3,188 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · derivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,188 Underlying: Common Stock · 3,188 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,623 | $116.79 | $189,550.49 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,651 F7 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,395 | $116.78 | $162,912.29 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,189 F5 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.90 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:27 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 824 | $116.85 | $96,285.80 |
DisclosureSEC source: 0001209191-21-009130 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,934 F3 · kind: Sale of 824 shares of common stock issued upon vesting of 2,430 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,606) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 7,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · derivative · entry 6 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 44,632 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 2,030 | $116.84 | $237,186.42 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,099 F7 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,856 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,826) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $118.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,395 | $116.76 | $162,880.06 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,273 F5 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.84. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:26 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 845 | $116.89 | $98,775.18 |
DisclosureSEC source: 0001209191-21-009128 · doc4.xml · nonDerivative · entry 2 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,018 F3 · kind: Sale of 845 shares of common stock issued upon vesting of 2,429 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,584) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC |
Cooke JulieChief Human Resources Officer
|
GrantRestricted Stock Unit · Derivative | 5,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 5 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,314 Underlying: Common Stock · 5,314 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC |
Cooke JulieChief Human Resources Officer
|
GrantStock Option · Derivative | 31,880 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · derivative · entry 4 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,880 Underlying: Common Stock · 31,880 shares Expires 2031-02-08 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 913 | $116.72 | $106,566.46 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · nonDerivative · entry 3 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,737 F5 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:24 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 425 | $116.76 | $49,623.04 |
DisclosureSEC source: 0001209191-21-009125 · doc4.xml · nonDerivative · entry 2 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,915 F3 · kind: Sale of 425 shares of common stock issued upon vesting of 1,215 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (790) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.2819. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:21 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 7,439 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009123 · doc4.xml · derivative · entry 4 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:21 UTC |
ROBERTS EIRYChief Medical Officer
|
GrantStock Option · Derivative | 44,632 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009123 · doc4.xml · derivative · entry 3 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,632 Underlying: Common Stock · 44,632 shares Expires 2031-02-08 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:21 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 1,623 | $116.83 | $189,607.30 |
DisclosureSEC source: 0001209191-21-009123 · doc4.xml · nonDerivative · entry 2 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,693 F3 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,085 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,462) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:21 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 740 | $116.67 | $86,336.61 |
DisclosureSEC source: 0001209191-21-009123 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,231 F1 · kind: Sale of 740 shares of common stock issued upon vesting of 2,126 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,386) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.98 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:20 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantRestricted Stock Unit · Derivative | 5,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009121 · doc4.xml · derivative · entry 6 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,314 Underlying: Common Stock · 5,314 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:20 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantStock Option · Derivative | 31,880 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009121 · doc4.xml · derivative · entry 5 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,880 Underlying: Common Stock · 31,880 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:20 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,015 | $116.87 | $118,624.47 |
DisclosureSEC source: 0001209191-21-009121 · doc4.xml · nonDerivative · entry 4 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,510 F7 · kind: Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.88. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:20 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,490 | $116.74 | $173,935.75 |
DisclosureSEC source: 0001209191-21-009121 · doc4.xml · nonDerivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,597 F5 · kind: Sale of 1,490 shares of common stock issued upon vesting of 2,650 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,160) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.99 to $117.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:20 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 756 | $116.89 | $88,368.99 |
DisclosureSEC source: 0001209191-21-009121 · doc4.xml · nonDerivative · entry 2 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,437 F3 · kind: Sale of 756 shares of common stock issued upon vesting of 1,518 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (762) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantRestricted Stock Unit · Derivative | 6,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · derivative · entry 6 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,376 Underlying: Common Stock · 6,376 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantStock Option · Derivative | 38,256 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,256 Underlying: Common Stock · 38,256 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,218 | $116.70 | $142,142.31 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 4 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,273 F7 · kind: Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 803 | $116.69 | $93,705.12 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 3 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,178 F5 · kind: Sale of 803 shares of common stock issued upon vesting of 1,525 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (722) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:18 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 687 | $116.67 | $80,151.81 |
DisclosureSEC source: 0001209191-21-009119 · doc4.xml · nonDerivative · entry 2 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,456 F3 · kind: Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.97 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:16 UTC |
Lippoldt DarinChief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 6,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009115 · doc4.xml · derivative · entry 12 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,908 Underlying: Common Stock · 6,908 shares Expires not disclosed F13 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F14 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F14 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:16 UTC |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 41,444 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009115 · doc4.xml · derivative · entry 11 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,444 Underlying: Common Stock · 41,444 shares Expires 2031-02-08 F12 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:16 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,522 | $116.72 | $177,649.51 |
DisclosureSEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,361 F7 · kind: Sale of 1,522 shares of common stock issued upon vesting of 2,892 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,370) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.95 to $117.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:16 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,198 | $116.74 | $139,858.83 |
DisclosureSEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,991 F5 · kind: Sale of 1,198 shares of common stock issued upon vesting of 2,275 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,077) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.01 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:16 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 687 | $116.69 | $80,165.89 |
DisclosureSEC source: 0001209191-21-009115 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,914 F3 · kind: Sale of 687 shares of common stock issued upon vesting of 1,974 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (1,287) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.90 to $117.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 17,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 6 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,269 Underlying: Common Stock · 17,269 shares Expires not disclosed F10 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F11 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. F11 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 8, 2022, February 8, 2023, February 8, 2024, and February 8, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 103,609 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · derivative · entry 5 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,609 Underlying: Common Stock · 103,609 shares Expires 2031-02-08 F9 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,248 | $116.71 | $379,089.35 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 4 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,972 F7 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F8 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.65. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 4,343 | $116.74 | $506,999.21 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 3 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,051 F5 · kind: Sale of 4,343 shares of common stock issued upon vesting of 8,250 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (3,907) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F6 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.89 to $117.86. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 02:17 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,875 | $116.79 | $335,774.99 |
DisclosureSEC source: 0001209191-21-009117 · doc4.xml · nonDerivative · entry 2 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,144 F3 · kind: Sale of 2,875 shares of common stock issued upon vesting of 5,770 restricted stock units on February 8, 2021 to cover payroll and withholding taxes, with the balance of the shares (2,895) maintained by the Reporting Person. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 at least 60 days prior to the transaction date in Box 3 above. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $115.91 to $117.89. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Mar 27, 2021 01:48 UTC Amendment |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023368 · doc4a.xml · derivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 27, 2021 01:48 UTC Amendment |
ABERNETHY MATTChief Financial Officer
|
GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023367 · doc4a.xml · derivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:24 UTC Amendment |
ROBERTS EIRYChief Medical Officer
|
GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023387 · doc4a.xml · derivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:23 UTC Amendment |
Lloyd-Smith MalcolmChief Regulatory Officer
|
GrantStock Option · Derivative | 35,035 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023385 · doc4a.xml · derivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,035 Underlying: Common Stock · 35,035 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:22 UTC Amendment |
Lippoldt DarinChief Legal Officer
|
GrantStock Option · Derivative | 45,546 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023383 · doc4a.xml · derivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,546 Underlying: Common Stock · 45,546 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:21 UTC Amendment |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantStock Option · Derivative | 42,042 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023381 · doc4a.xml · derivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,042 Underlying: Common Stock · 42,042 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:19 UTC Amendment |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
GrantStock Option · Derivative | 113,863 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023379 · doc4a.xml · derivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,863 Underlying: Common Stock · 113,863 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 08, 2021 Filed Mar 29, 2021 10:15 UTC Amendment |
Gano KyleChief Business Development Off
|
GrantStock Option · Derivative | 49,049 | $0.00 Strike: $117.63 | $0.00 |
DisclosureSEC source: 0001209191-21-023376 · doc4a.xml · derivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,049 Underlying: Common Stock · 49,049 shares Expires 2031-02-08 F1 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.